當(dāng)前位置：首頁(yè) JCRQ1 期刊介紹(非官網(wǎng))

Expert Opinion On Therapeutic TargetsSCIE

國(guó)際簡(jiǎn)稱：EXPERT OPIN THER TAR 參考譯名：治療靶點(diǎn)專家意見

中科院分區(qū)
2區(qū)
CiteScore分區(qū)
Q1
JCR分區(qū)
Q1

基本信息：: ISSN：1472-8222; E-ISSN：1744-7631; 是否OA：未開放; 是否預(yù)警：否; TOP期刊：是

出版信息：: 出版地區(qū)：ENGLAND; 出版商：Taylor and Francis Ltd.; 出版語(yǔ)言：English; 出版周期：Monthly; 出版年份：2001; 研究方向：醫(yī)學(xué)-藥學(xué)

評(píng)價(jià)信息：: 影響因子：4.6; H-index：78; CiteScore指數(shù)：8.9; SJR指數(shù)：1.423; SNIP指數(shù)：0.975

發(fā)文數(shù)據(jù)：: Gold OA文章占比：13.79%; 研究類文章占比：23.66%; 年發(fā)文量：93; 自引率：0.0172...; 開源占比：0.089; 出版撤稿占比：0; 出版國(guó)人文章占比：0.06; OA被引用占比：0.0027...

投稿咨詢加急見刊

英文簡(jiǎn)介期刊介紹 CiteScore數(shù)據(jù) 中科院SCI分區(qū) JCR分區(qū) 發(fā)文數(shù)據(jù) 常見問(wèn)題

英文簡(jiǎn)介Expert Opinion On Therapeutic Targets期刊介紹

The journal evaluates molecules, signalling pathways, receptors and other therapeutic targets and their potential as candidates for drug development. Articles in this journal focus on the molecular level and early preclinical studies. Articles should not include clinical information including specific drugs and clinical trials.

The Editors welcome:

Reviews covering novel disease targets at the molecular level and information on early preclinical studies and their implications for future drug development.

Articles should not include clinical information including specific drugs and clinical trials.

Original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugs.

The audience consists of scientists, managers and decision makers in the pharmaceutical industry, academic researchers working in the field of molecular medicine and others closely involved in R&D.

期刊簡(jiǎn)介Expert Opinion On Therapeutic Targets期刊介紹

《Expert Opinion On Therapeutic Targets》自2001出版以來(lái)，是一本醫(yī)學(xué)優(yōu)秀雜志。致力于發(fā)表原創(chuàng)科學(xué)研究結(jié)果，并為醫(yī)學(xué)各個(gè)領(lǐng)域的原創(chuàng)研究提供一個(gè)展示平臺(tái)，以促進(jìn)醫(yī)學(xué)領(lǐng)域的的進(jìn)步。該刊鼓勵(lì)先進(jìn)的、清晰的闡述，從廣泛的視角提供當(dāng)前感興趣的研究主題的新見解，或?qū)彶槎嗄陙?lái)某個(gè)重要領(lǐng)域的所有重要發(fā)展。該期刊特色在于及時(shí)報(bào)道醫(yī)學(xué)領(lǐng)域的最新進(jìn)展和新發(fā)現(xiàn)新突破等。該刊近一年未被列入預(yù)警期刊名單，目前已被權(quán)威數(shù)據(jù)庫(kù)SCIE收錄，得到了廣泛的認(rèn)可。

該期刊投稿重要關(guān)注點(diǎn)：

預(yù)計(jì)審稿時(shí)間：偏慢,4-8周
國(guó)際TOP期刊
醫(yī)學(xué)
PHARMACOLOGY & PHARMACY
SCIE
中科院2區(qū)
非預(yù)警

Cite Score數(shù)據(jù)（2024年最新版）Expert Opinion On Therapeutic Targets Cite Score數(shù)據(jù)

CiteScore：8.9
SJR：1.423
SNIP：0.975

學(xué)科類別	分區(qū)	排名	百分位
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Pharmacology	Q1	52 / 313	83%
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Drug Discovery	Q1	29 / 157	81%
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Clinical Biochemistry	Q1	23 / 117	80%
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Molecular Medicine	Q1	43 / 178	76%

CiteScore 是由Elsevier(愛思唯爾)推出的另一種評(píng)價(jià)期刊影響力的文獻(xiàn)計(jì)量指標(biāo)。反映出一家期刊近期發(fā)表論文的年篇均引用次數(shù)。CiteScore以Scopus數(shù)據(jù)庫(kù)中收集的引文為基礎(chǔ)，針對(duì)的是前四年發(fā)表的論文的引文。CiteScore的意義在于，它可以為學(xué)術(shù)界提供一種新的、更全面、更客觀地評(píng)價(jià)期刊影響力的方法，而不僅僅是通過(guò)影響因子(IF)這一單一指標(biāo)來(lái)評(píng)價(jià)。

歷年Cite Score趨勢(shì)圖

中科院SCI分區(qū)Expert Opinion On Therapeutic Targets 中科院分區(qū)

中科院 2023年12月升級(jí)版 綜述期刊：是 Top期刊：否

大類學(xué)科	分區(qū)	小類學(xué)科	分區(qū)
醫(yī)學(xué)	2區(qū)	PHARMACOLOGY & PHARMACY 藥學(xué)	2區(qū)

中科院分區(qū)表 是以客觀數(shù)據(jù)為基礎(chǔ)，運(yùn)用科學(xué)計(jì)量學(xué)方法對(duì)國(guó)際、國(guó)內(nèi)學(xué)術(shù)期刊依據(jù)影響力進(jìn)行等級(jí)劃分的期刊評(píng)價(jià)標(biāo)準(zhǔn)。它為我國(guó)科研、教育機(jī)構(gòu)的管理人員、科研工作者提供了一份評(píng)價(jià)國(guó)際學(xué)術(shù)期刊影響力的參考數(shù)據(jù)，得到了全國(guó)各地高校、科研機(jī)構(gòu)的廣泛認(rèn)可。

中科院分區(qū)表 將所有期刊按照一定指標(biāo)劃分為1區(qū)、2區(qū)、3區(qū)、4區(qū)四個(gè)層次，類似于“優(yōu)、良、及格”等。最開始，這個(gè)分區(qū)只是為了方便圖書管理及圖書情報(bào)領(lǐng)域的研究和期刊評(píng)估。之后中科院分區(qū)逐步發(fā)展成為了一種評(píng)價(jià)學(xué)術(shù)期刊質(zhì)量的重要工具。

歷年中科院分區(qū)趨勢(shì)圖

JCR分區(qū)Expert Opinion On Therapeutic Targets JCR分區(qū)

2023-2024 年最新版

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：PHARMACOLOGY & PHARMACY	SCIE	Q1	57 / 354	84%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：PHARMACOLOGY & PHARMACY	SCIE	Q2	125 / 354	64.83%

JCR分區(qū)的優(yōu)勢(shì)在于它可以幫助讀者對(duì)學(xué)術(shù)文獻(xiàn)質(zhì)量進(jìn)行評(píng)估。不同學(xué)科的文章引用量可能存在較大的差異，此時(shí)單獨(dú)依靠影響因子(IF)評(píng)價(jià)期刊的質(zhì)量可能是存在一定問(wèn)題的。因此，JCR將期刊按照學(xué)科門類和影響因子分為不同的分區(qū)，這樣讀者可以根據(jù)自己的研究領(lǐng)域和需求選擇合適的期刊。

歷年影響因子趨勢(shì)圖

發(fā)文數(shù)據(jù)

2023-2024 年國(guó)家/地區(qū)發(fā)文量統(tǒng)計(jì)

國(guó)家/地區(qū)數(shù)量
USA107
Italy37
GERMANY (FED REP GER)29
CHINA MAINLAND23
England19
Canada15
Australia14
Spain14
Austria8
Iran8

本刊中國(guó)學(xué)者近年發(fā)表論文

1、Targeting endoplasmic reticulum stress-the responder to lipotoxicity and modulator of non-alcoholic fatty liver diseases
Author: Luo, Yu; Jiao, Qiangqiang; Chen, Yuping

Journal: EXPERT OPINION ON THERAPEUTIC TARGETS. 2023; Vol. , Issue , pp. -. DOI: 10.1080/14728222.2022.2170780
2、The participation of non-canonical autophagic proteins in the autophagy process and their potential as therapeutic targets
Author: Yin, Yiming; Zhou, Yourong; Yang, Xiaochun; Xu, Zhifei; Yang, Bo; Luo, Peihua; Yan, Hao; He, Qiaojun

Journal: EXPERT OPINION ON THERAPEUTIC TARGETS. 2023; Vol. , Issue , pp. -. DOI: 10.1080/14728222.2023.2177151
3、Novel therapeutic perspectives for crescentic glomerulonephritis through targeting parietal epithelial cell activation and proliferation
Author: Huang, Yanjie; Zhao, Xueru; Zhang, Qiushuang; Yang, Xiaoqing; Hou, Gailing; Peng, Chaoqun; Jia, Mengzhen; Zhou, Li; Yamamoto, Tatsuo; Zheng, Jian

Journal: EXPERT OPINION ON THERAPEUTIC TARGETS. 2023; Vol. , Issue , pp. -. DOI: 10.1080/14728222.2023.2177534
4、Recent advances of Phosphodiesterase 4B in cancer
Author: Miao, Yu; Peng, Li; Chen, Zhaolin; Hu, Ying; Tao, Liangsong; Yao, Yan; Wu, Yincui; Yang, Dashuai; Xu, Tao

Journal: EXPERT OPINION ON THERAPEUTIC TARGETS. 2023; Vol. 27, Issue 2, pp. 121-132. DOI: 10.1080/14728222.2023.2183496
5、Papain exerts an anti-atherosclerosis effect with suppressed MPA-mediated foam cell formation by regulating the MAPK and PI3K/Akt-NF-kappa B pathways
Author: Fei, Xianming; Pan, Lianlian; Yuan, Wufen; Zhao, Yan; Jiang, Lei; Huang, Qinghua; Wu, Yan; Ru, Guoqing

Journal: EXPERT OPINION ON THERAPEUTIC TARGETS. 2023; Vol. 27, Issue 3, pp. 239-250. DOI: 10.1080/14728222.2023.2194531
6、Treatment update for vitiligo based on autoimmune inhibition and melanocyte protection
Author: Xie, Bo; Zhu, Yuqi; Shen, Yuqing; Xu, Wen; Song, Xiuzu

Journal: EXPERT OPINION ON THERAPEUTIC TARGETS. 2023; Vol. 27, Issue 3, pp. 189-206. DOI: 10.1080/14728222.2023.2193329
7、Targeting the cell signaling pathway Keap1-Nrf2 as a therapeutic strategy for adenocarcinomas of the lung.
Author: Zhang B^1,², Ma Z¹, Tan B¹, Lin N^1,².

Journal: Expert Opin Ther Targets. 2019 Mar;23(3):241-250. doi: 10.1080/14728222.2019.1559824. Epub 2018 Dec 27.
8、The P2X7 receptor: a new therapeutic target in Alzheimer's disease.
Author: Illes P^1,², Rubini P², Huang L², Tang Y².

Journal: Expert Opin Ther Targets. 2019 Mar;23(3):165-176. doi: 10.1080/14728222.2019.1575811.